Five Additional Leading Physicians to Join Cellectis Clinical Advisory Board

« return
news

Five Additional Leading Physicians to Join Cellectis Clinical Advisory Board

New Board Members Include Hematology Experts Catherine Bollard, Hervé Dombret, Ola Landgren, Marcela Maus & Dietger Niederweiser

 

March 7, 2017 – New York (N.Y.) – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART), today announced five new leading experts will join the Company’s Clinical Advisory Board (CAB) in 2017 from the fields of hematologic malignancies, immunotherapy, immunology, stem cell transplantation. The CAB serves as a strategic resource to Cellectis as the Company enters the clinical development of allogeneic CAR T immunotherapies, led by its wholly owned product candidate, UCART123.

Read the press release download